Roflumilast attenuates allergen-induced inflammation in mild asthmatic subjects

[1]  A. Hatzelmann,et al.  The preclinical pharmacology of roflumilast--a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease. , 2010, Pulmonary pharmacology & therapeutics.

[2]  J. Cowan,et al.  Effects of steroid therapy on inflammatory cell subtypes in asthma , 2009, Thorax.

[3]  F. Martinez,et al.  Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials , 2009, The Lancet.

[4]  F. Martinez,et al.  Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials , 2009, The Lancet.

[5]  C. Lemière,et al.  Differences in airway cytokine profile in severe asthma compared to moderate asthma. , 2008, Chest.

[6]  J. Klar,et al.  Roflumilast inhibits leukocyte‐endothelial cell interactions, expression of adhesion molecules and microvascular permeability , 2007, British journal of pharmacology.

[7]  L. Boulet,et al.  The allergen bronchoprovocation model: an important tool for the investigation of new asthma anti‐inflammatory therapies , 2007, Allergy.

[8]  K. Rabe,et al.  Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD , 2007, Thorax.

[9]  M. Conti,et al.  Differential Expression and Function of Phosphodiesterase 4 (PDE4) Subtypes in Human Primary CD4+ T Cells: Predominant Role of PDE4D1 , 2007, The Journal of Immunology.

[10]  Jie Zhu,et al.  Bronchial mucosal inflammation and upregulation of CXC chemoattractants and receptors in severe exacerbations of asthma , 2007, Thorax.

[11]  R. Hermann,et al.  Roflumilast, a once-daily oral phosphodiesterase 4 inhibitor, lacks relevant pharmacokinetic interactions with inhaled salbutamol when co-administered in healthy subjects. , 2006, International journal of clinical pharmacology and therapeutics.

[12]  P. Bardin,et al.  Roflumilast, a Phosphodiesterase 4 Inhibitor, Reduces Airway Hyperresponsiveness after Allergen Challenge , 2006, Respiration.

[13]  E. Bateman,et al.  Efficacy and safety of roflumilast in the treatment of asthma. , 2006, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[14]  P. Bardin,et al.  Roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor, attenuates allergen-induced asthmatic reactions. , 2005, The Journal of allergy and clinical immunology.

[15]  K. Chung,et al.  Increase in airway neutrophils after oral but not inhaled corticosteroid therapy in mild asthma. , 2005, Respiratory medicine.

[16]  V. Madden,et al.  Type 4A cAMP-specific phosphodiesterase is stored in granules of human neutrophils and eosinophils , 2003, Cell and Tissue Research.

[17]  K. Rabe,et al.  Does a single dose of the phosphodiesterase 4 inhibitor, cilomilast (15 mg), induce bronchodilation in patients with chronic obstructive pulmonary disease? , 2003, Pulmonary pharmacology & therapeutics.

[18]  S. Durham,et al.  Basophil recruitment and IL-4 production during human allergen-induced late asthma. , 2001, The Journal of allergy and clinical immunology.

[19]  A. Hatzelmann,et al.  Anti-Inflammatory and Immunomodulatory Potential of the Novel PDE 4 Inhibitor Roflumilast in Vitro , 2001 .

[20]  P. O'Byrne,et al.  Increased numbers of both airway basophils and mast cells in sputum after allergen inhalation challenge of atopic asthmatics. , 2000, American journal of respiratory and critical care medicine.

[21]  P. O'Byrne,et al.  Kinetics of allergen-induced airway eosinophilic cytokine production and airway inflammation. , 1999, American journal of respiratory and critical care medicine.

[22]  F. Gantner,et al.  Therapeutic potential of selective PDE inhibitors in asthma. , 1999, Pulmonary pharmacology & therapeutics.

[23]  Ikai,et al.  Cyclic adenosine monophosphate phosphodiesterase activity in peripheral blood mononuclear leucocytes from patients with atopic dermatitis: correlation with respiratory atopy , 1998, The British journal of dermatology.

[24]  S. Holgate,et al.  The effect of a novel orally active selective PDE4 isoenzyme inhibitor (CDP840) on allergen-induced responses in asthmatic subjects. , 1997, The European respiratory journal.

[25]  P. Barnes,et al.  Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD. , 1997, American journal of respiratory and critical care medicine.

[26]  M. Jordana,et al.  Effects of inhaled budesonide on allergen-induced airway responses and airway inflammation. , 1996, American journal of respiratory and critical care medicine.

[27]  F. Hargreave,et al.  Indices of airway inflammation in induced sputum: reproducibility and validity of cell and fluid-phase measurements. , 1996, American journal of respiratory and critical care medicine.

[28]  J. Beavo,et al.  Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. , 1995, Physiological reviews.

[29]  J. Hanifin,et al.  Monocyte phosphodiesterase abnormalities and dysregulation of lymphocyte function in atopic dermatitis. , 1995, The Journal of investigative dermatology.

[30]  H. Boushey,et al.  Comparison of samples collected by sputum induction and bronchoscopy from asthmatic and healthy subjects. , 1995, American journal of respiratory and critical care medicine.

[31]  M. Jordana,et al.  Effects of allergen challenge on eosinophils, eosinophil cationic protein, and granulocyte-macrophage colony-stimulating factor in mild asthma. , 1995, American journal of respiratory and critical care medicine.

[32]  J. D. de Monchy,et al.  Allergen-induced recruitment of inflammatory cells in lavage 3 and 24 h after challenge in allergic asthmatic lungs. , 1993, Chest.

[33]  S. Durham,et al.  Increases in activated T lymphocytes, eosinophils, and cytokine mRNA expression for interleukin-5 and granulocyte/macrophage colony-stimulating factor in bronchial biopsies after allergen inhalation challenge in atopic asthmatics. , 1993, American journal of respiratory cell and molecular biology.

[34]  D. Cockcroft,et al.  Prediction of airway responsiveness to allergen from skin sensitivity to allergen and airway responsiveness to histamine. , 2015, The American review of respiratory disease.

[35]  P. O'Byrne,et al.  Late asthmatic responses. , 1987, The American review of respiratory disease.

[36]  C. Falliers.  AIRWAY RESPONSIVENESS—MEASUREMENT AND INTERPRETATION , 1986 .